GALECTIN THERAPEUTICS INC. Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired
GALECTIN THERAPEUTICS INC. (GALT) reported Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired of $400.00 thousand for the 1-month period ending 2014-01-31, per its 10-Q filed 2014-11-10.
Discontinued › Notes
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired · last filed 2014-11-10
- 2014-01-31: Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired 1 month $400.00K.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired 1 month |
|---|---|
| 2014-01-31 | $400.00K 10-Q · filed 2014-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |